Insider Selling: Progyny (NASDAQ:PGNY) EVP Sells $13,032.70 in Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 530 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $24.59, for a total value of $13,032.70. Following the completion of the transaction, the executive vice president directly owned 72,719 shares in the company, valued at $1,788,160.21. This trade represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Progyny Trading Up 1.8%

Progyny stock opened at $25.17 on Thursday. Progyny, Inc. has a 12 month low of $13.86 and a 12 month high of $27.51. The stock has a fifty day simple moving average of $22.25 and a two-hundred day simple moving average of $22.31. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 39.95, a PEG ratio of 1.95 and a beta of 0.97.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.39 by $0.06. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The company had revenue of $313.35 million for the quarter, compared to analysts’ expectations of $299.23 million. During the same period last year, the firm posted $0.11 earnings per share. Progyny’s revenue was up 9.3% compared to the same quarter last year. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. On average, equities research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on PGNY shares. KeyCorp raised Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price objective for the company in a report on Tuesday, November 11th. JPMorgan Chase & Co. raised their price objective on shares of Progyny from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Tuesday, November 11th. Barclays started coverage on Progyny in a research note on Monday. They issued an “overweight” rating and a $29.00 price target for the company. Canaccord Genuity Group increased their price objective on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a report on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $27.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in PGNY. Barclays PLC boosted its holdings in Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after acquiring an additional 696,447 shares during the period. Nuveen LLC bought a new stake in Progyny during the 1st quarter valued at about $13,645,000. Ameriprise Financial Inc. grew its stake in Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after acquiring an additional 545,431 shares in the last quarter. Jupiter Asset Management Ltd. purchased a new position in shares of Progyny during the second quarter worth approximately $10,525,000. Finally, Nomura Holdings Inc. bought a new stake in shares of Progyny during the second quarter valued at approximately $9,368,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.